Two new antiviral agents, compound 164, also known as 2'-nor-cGMP {9-[(2-hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]-guanine P-oxide}, and compound 102 [4-amino-5-bromo-7-(2-hydroxyethoxymethyl)-pyrrolo(2,3-d)pyrimidine], together with acyclovir for comparison, were evaluated for activities against the guinea pig lymphotropic herpesvirus infection in vitro by plaque reduction and virus yield reduction assays in guinea pig embryo cells. The two new compounds were demonstrated to be more potent against guinea pig lymphotropic herpesvirus infections than acyclovir. Compound 164 was the most potent of the three; drug concentrations required to reduce the number of plaques by 50% were 2, 35.5, and 144.5 ,IM for compounds 164, 102, and acyclovir, respectively. The two new compounds were cytostatic but not cytotoxic to guinea pig embryo cells in cultures. Attempts were made to investigate the inhibition of viral replication by these compounds, and the influence of test conditions on antiviral evaluations is discussed.
Guinea pig lymphotropic herpesvirus (GPHLV) was originally isolated from tissues of latently infected strain 2 guinea pigs (17) and subsequently from Hartley guinea pigs by cocultivation with susceptible guinea pig cells (17, 18) . GPHLV can be readily propagated in cultured guinea pig cells in vitro and produces characteristic cytopathic effect (CPE) . This system provides a convenient tool for quantitative assay of the virus. GPHLV infection in guinea pigs, however, only manifests as a transient lymphoproliferative change followed by a lifetime latent infection with the virus mainly found in the mononuclear cells, particularly the B lymphocytes (10) . Previous studies in our laboratory have shown that GPHLV shares a variety of biological properties with a human B lymphotropic herpesvirus, Epstein-Barr virus (EBV) (9, 10, 12, (14) (15) (16) (17) (18) 21) . EBV infection has been associated with an opportunistic infection in acquired immune deficiency syndrome or other immunocompromised patients in addition to its association with infectious mononucleosis, Burkitt's lymphoma, and nasopharyngeal carcinoma. Because a practical and convenient in vitro assay system or a suitable animal model is lacking, it has been very difficult to evaluate antiviral agents against EBV infection. With a view that GPHLV might share some of its antiviral susceptibilities with EBV, we tested two new compounds, compound 164 (7), 9-[(2-hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]-guanine P-oxide, and compound 102, 4-amino-5-bromo-7-(2-hydroxyethoxymethyl)-pyrrolo (2,3-d) pyrimidine, for their activities against GPHLV infection in guinea pig embryo (GPE) cell culture. For comparison, the well-established antiherpesvirus drug acyclovir (ACV) was included. Inhibition of viral replication by compounds 164 and 102 was also investigated.
MATERIALS AND METHODS
Cell culture, virus strain, and infectivity assay. Primary GPE cell cultures were prepared from 30-to 40-day-old embryos of Hartley guinea pigs (Camm Research Institute, Wayne, N.J.) as described previously (13) . The cells were grown in minimum essential medium-Earle salt solution supplemented with 10% newborn calf sera and maintained in that medium with 2% newborn calf sera when the cell monolayers were confluent. Both primary and secondary (passaged three to four times) GPE cells were used. GPHLV strain LK40 was originally isolated from the blood of a leukemic guinea pig (18) and was used throughout this study. The stock virus was prepared in GPE cells. The infectivity titer of the stock virus was 5 to 6 log10 50% tissue culture infective doses per 0.1 ml.
For virus infectivity assay, serial 10-fold dilutions of GPHLV were made in Hanks balanced salt solution, and virus infectivity titers were determined in GPE cell cultures grown in 24-well culture panels by either end-point titration or plaque assay and expressed as log1o 50% tissue culture infective dose or PFU per 0.1 ml, respectively. For plaque assay, GPHLV-infected cell cultures were overlaid with media containing minimum essential medium-Earle salt solution, 5% newborn calf sera, and 0.5% methylcellulose and incubated at 35°C for about 7 days. Plaques were enumerated from infected cultures, which were fixed and stained with a solution containing 5% Formalin, 20% ethanol, and 1% crystal violet. compounds were added. The infected cell cultures were incubated for about 7 days and then fixed and stained, and virus-induced plaques were enumerated. By using as reference the number of plaques obtained in the controls (untreated and infected cultures), the drug concentrations required to reduce the number of plaques by 50% (ED50) were calculated from the dose-response curves.
Virus yield reduction assay. GPE cell monolayers were infected with GPHLV at a multiplicity of infection (MOI) of 1 (unless otherwise indicated). After 2 h of adsorption, the unadsorbed viruses were removed by washing with Hanks balanced salt solution three times; then maintenance media containing various concentrations of the test compounds were added. At 48 h after infection (unless otherwise indicated), the virus yield was harvested after alternate freezing and thawing of infected cultures three times. The virus yield was determined by plaque assay in GPE cells. By using as reference virus yield in the controls (untreated and infected cultures), the drug concentrations required to reduce the virus yield by 90% (ED90) and 99% (EDg9) were calculated from the dose-response curves.
In an experiment with compound 102, two different virus challenge doses at MOIs of 10 and 0.01 were used. Virus yield was harvested and assayed when the advanced GPHLV-induced CPE appeared. In another experiment with all three antiviral compounds, a constant MOI of 1 was used and the virus yield was harvested and assayed at 24 and 48 h after infection.
Ultrastructural studies. GPE monolayer cell cultures grown in 60-mm petri dishes were infected with GPHLV at an MOI of 5 to 10. After 2 h of adsorption, the unadsorbed viruses were removed by washing with Hanks balanced salt solution three times and maintenance media with various concentrations of compound 164 or 102 were added; the infected cells were incubated until the virus-infected control (without drug) cultures showed advanced CPE (about 2 to 3 days postinfection). Infected GPE monolayer cells were then fixed, scraped off, and centrifuged. The cell pellets were washed with 0.1 p.M cacodylate buffer solution and postfixed with 1.33% osmium tetroxide in S-collidine buffer for 1 h. Cell pellets were embedded in Epon, stained with uranyl acetate and lead citrate, and examined under a Philips EM 300 electron microscope (8) .
Effect of duration of treatment. To determine the stage of virus replication in which the compounds exerted maximum activities, the drug addition and removal experiment was performed as follows. GPE cell monolayers were infected with GPHLV at a high MOI of 5. At various times after virus adsorption, compound 164 (200 ,uM) or 102 (400 puM) was either added to or removed from the infected cultures and incubation was continued until 48 h postadsorption, when the virus yields were harvested and assayed. In both drug addition and removal experiments, 48-h drug-treated and drug-free controls were included.
Cytotoxicity assays. Various concentrations of the compounds were added to confluent GPE cell monolayer cultures or rapidly replicating cells (24 h after seeding) and maintained for 4 days. The viable cell counts of each culture were determined daily in quadruplicate by the trypan blue exclusion method, using a hemacytometer. Drug concentrations required to reduce the viable cell counts by 50% (CyD50) were calculated by reference to the counts obtained in the control (without drug) cultures.
RESULTS
Effect on GPHLV replication. By plaque reduction assay, both of the two new compounds, 164 and 102, showed 20 to 70 times higher potencies against GPHLV infection in GPE cell cultures when compared with ACV. The ED50s were 2.0, 35.5, and 144.5 ,uM for compounds 164, 102, and ACV, respectively. By virus yield reduction assay, these two new compounds were also more potent than ACV; the calculated ED90 and ED99 were 0.9 and 3.5, 160 and 400, and 354 and 1,200 ,uM for compounds 164, 102, and ACV, respectively. The relative potencies of the three antiviral compounds were consistent in both of the assay methods: compound 164 > compound 102 > ACV (Table 1) .
Cytotoxicity to and therapeutic index in stationary cultured GPE cells. The stationary GPE cells were shown to be resistant against the toxic effects of both compounds; drug concentrations of 330 (compound 164), 700 (compound 102), (Fig. 2A) . However, when infected cultures were treated with either compound 164 or compound 102, the intranuclear virus packages were absent. Nucleocapsid and core formations were inhibited, with the majority of the capsids lacking dense cores. Extracellular virions were rarely found ( Fig. 2B and C Compound 164 is a cyclically phosphorylated derivative of another antiherpesvirus drug, 9-(1,3-dihydroxy-2-propoxymethyl)-guanine. Previous studies have shown that compound 164 has a broad spectrum of antiviral activity against many DNA viruses, including the herpesvirus group, such as herpes simplex virus and cytomegalovirus, and its antiviral effect was independent of the viral thymidine kinase. Furthermore, it has been shown that the antiviral activity of compound 164 does not correlate with the intracellular 9-(1,3-dihydroxy-2-propoxymethyl)-guanine triphosphate level, and it has an antiviral mechanism different and apart from that of known acyclonucleosides, e.g., 9-(1,3-dihy- TI ME POST-ABSORPTION (h) The cytotoxicity of the two compounds was determined by the trypan blue exclusion method, using both stationary and replicating GPE cells. The stationary cells were found to be resistant to both compounds, but the replicating cells seemed to be more sensitive to the cytostatic effect of the two compounds. Both compounds inhibited the GPE cell growth rate by 50% at a concentration of about 10 to 20 F.M. Previous results showed that the CyD50 of compound 164 against human fibroblast cell (MRC-5) growth was about 150 ,uM (7, 22) and that of compound 102 against human embryo fibroblast cells, monkey kidney cells (BSC-1), or human neoplastic cell line KB was about 100 F.M, as determined by visual observation or measurement of cellular RNA and protein syntheses (Drach et al., Antiviral Res. 9:81, 1988). These apparent discrepancies could be due to the differences in the sensitivity of the various types of cells used or the different methods used for testing.
As mentioned earlier, GPHLV has been demonstrated to share many characteristics with human EBV. Preliminary data from this laboratory revealed that GPHLV may share some antiviral susceptibilities with EBV; i.e., GPHLV was shown to be relatively resistant to ACV but very susceptible to 2'-fluoro-5-methyl-arabinosyl-uracil (unpublished data from this laboratory). The high potencies of the two new compounds tested here (notably, compound 164) indicate that they warrant further studies for antiviral treatment against EBV infection. With the increasing interest in EBV infection in patients with acquired immune deficiency syndrome and the need for anti-EBV treatment, GPHLV infection in both cell cultures and guinea pigs would be a valuable model for evaluating antiviral agents against EBV infections.
